Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 6,080.00
+10.00 (0.16%)
At close: Dec 5, 2025
Kyongbo Pharmaceutical Revenue
Kyongbo Pharmaceutical had revenue of 66.99B KRW in the quarter ending September 30, 2025, with 15.04% growth. This brings the company's revenue in the last twelve months to 252.20B, up 4.86% year-over-year. In the year 2024, Kyongbo Pharmaceutical had annual revenue of 238.56B with 10.26% growth.
Revenue (ttm)
252.20B
Revenue Growth
+4.86%
P/S Ratio
0.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
145.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238.56B | 22.20B | 10.26% |
| Dec 31, 2023 | 216.36B | 20.09B | 10.24% |
| Dec 31, 2022 | 196.26B | 25.61B | 15.00% |
| Dec 31, 2021 | 170.66B | -44.63B | -20.73% |
| Dec 31, 2020 | 215.29B | 23.58B | 12.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |